Vol. 126 No. 2 (2022)
Original Article

Presepsin: a biomarker of early-onset neonatal sepsis

Valentina Botondi
Neonatal Intensive Care Unit, G. d’Annunzio University, Chieti
Ebe D’Adamo
Neonatal Intensive Care Unit, G. d’Annunzio University, Chieti
Oriana Trubiani
Department of Innovative Technologies in Medicine & Dentistry, University “G. D’Annunzio”, Chieti
Diego Gazzolo
Neonatal Intensive Care Unit, G. d’Annunzio University, Chieti
Published December 27, 2022
Keywords
  • presepsin,
  • newborns,
  • early onset sepsis
How to Cite
Botondi, V., D’Adamo, E., Trubiani, O., & Gazzolo, D. (2022). Presepsin: a biomarker of early-onset neonatal sepsis. Italian Journal of Anatomy and Embryology, 126(2), 43-52. https://doi.org/10.36253/ijae-13787

Abstract

Neonatal early-onset sepsis represents one of the most common diseases leading to morbidity and mortality in preterm infants. A prompt diagnosis is still a challenge in the clinical practice due to several biases affecting the current standard of care performance. In this regard, the soluble cluster of differentiation CD14 subtype, namely Presepsin, has been shown to be a promising diagnostic biomarker of sepsis in newborns. Although Presepsin provides high accuracy and short results output, its reliability in daily clinical practice is still an issue that needs further investigation. Therefore, in the present review we offer an overview of Presepsin role as diagnostic tool of early-neonatal onset sepsis.

Metrics

Metrics Loading ...